Theralink Technologies, Inc. (THER)
Theralink Technologies, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Golden, CO, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $615,149. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -5093.6%. Its beta of 8.99 implies it has historically moved more than the broad market.
Theralink Technologies, Inc., headquartered in Golden, Colorado, is a commercial-stage enterprise specializing in precision medicine and the generation of crucial molecular data. The company is dedicated to advancing and bringing to market innovative cancer immunotherapy products. Utilizing its proprietary platform, which focuses on phosphoprotein and protein biomarkers, alongside its sophisticated laboratory-developed test (LDT) technology, Theralink addresses diverse aspects of oncology and pharmaceutical research. Through their specialized Theralink Reverse Phase Protein Array assays, they provide highly accurate oncology data. This information enables the biopharmaceutical industry and clinical oncologists to more precisely predict which patients will respond to, or be resistant to, both FDA-approved and investigational drug treatments. Ultimately, Theralink's diagnostic assays deliver vital, actionable insights that benefit physicians, patients, and biopharmaceutical companies operating within the field of cancer care. The company adopted its current name, Theralink Technologies, Inc., in September 2020, having previously operated as OncBioMune Pharmaceuticals, Inc.
Theralink Technologies, Inc. is most often compared with the following Healthcare names: